Future medicinal chemistry · 2025
Structural insights into Arylidenehydrazinyl Benzenesulfonamides as potent mycobacterial carbonic anhydrase inhibitors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumar Pardeep, Singampalli Anuradha, Bandela Rani, Bellapukonda Sri Mounika, Maddipatla Sarvan, Dalal Aman, Devi Ankita, Nanduri Srinivas, Kalia Nitin Pal, Paoletti Niccolo, Supuran Claudiu T, Madhavi Yaddanapudi Venkata
Аннотация
AIMS: To design, synthesize, and assess novel sulfonamide hydrazone derivatives as selective inhibitors of Mycobacterium tuberculosis carbonic anhydrase.
MATERIALS AND METHODS: Two series of 4-(arylidenehydrazinyl)benzenesulfonamides (5a-r) and N-arylidene-4-methylbenzenesulfonohydrazides (6a-h) were synthesized and evaluated against recombinant MtCA isoforms 1 and 3, and human carbonic anhydrase isoforms I and II by enzyme inhibition assays. Molecular docking and molecular dynamics simulations assessed the binding stability and coordination with the active-site zinc ion. Anti-mycobacterial activity was determined by minimum inhibitory concentrations (MICs) against M. tuberculosis. Time-kill kinetics and cytotoxicity assays evaluated the bactericidal potential and selectivity of the compound toward mammalian cells.
RESULTS: The compounds showed potent inhibition of MtCA 3 and hCA II, with moderate activity against MtCA 1 and hCA I. Notably, compounds 3e and 3f exhibited Ki values of 0.0931 µM and 0.0984 µM, respectively, surpassing acetazolamide (Ki = 0.104 µM). Docking and simulations confirmed stable zinc coordination. MIC values ranged from 4 to 128 µg/mL. Time-kill and cytotoxicity studies confirmed rapid bactericidal activity and low mammalian toxicity.
CONCLUSION: These sulfonamide hydrazone derivatives demonstrate potent, selective MtCA inhibition, robust antimycobacterial efficacy, and favorable safety profiles, representing promising scaffolds for novel tuberculosis therapies with a novel mode of action.
MATERIALS AND METHODS: Two series of 4-(arylidenehydrazinyl)benzenesulfonamides (5a-r) and N-arylidene-4-methylbenzenesulfonohydrazides (6a-h) were synthesized and evaluated against recombinant MtCA isoforms 1 and 3, and human carbonic anhydrase isoforms I and II by enzyme inhibition assays. Molecular docking and molecular dynamics simulations assessed the binding stability and coordination with the active-site zinc ion. Anti-mycobacterial activity was determined by minimum inhibitory concentrations (MICs) against M. tuberculosis. Time-kill kinetics and cytotoxicity assays evaluated the bactericidal potential and selectivity of the compound toward mammalian cells.
RESULTS: The compounds showed potent inhibition of MtCA 3 and hCA II, with moderate activity against MtCA 1 and hCA I. Notably, compounds 3e and 3f exhibited Ki values of 0.0931 µM and 0.0984 µM, respectively, surpassing acetazolamide (Ki = 0.104 µM). Docking and simulations confirmed stable zinc coordination. MIC values ranged from 4 to 128 µg/mL. Time-kill and cytotoxicity studies confirmed rapid bactericidal activity and low mammalian toxicity.
CONCLUSION: These sulfonamide hydrazone derivatives demonstrate potent, selective MtCA inhibition, robust antimycobacterial efficacy, and favorable safety profiles, representing promising scaffolds for novel tuberculosis therapies with a novel mode of action.